SCHEMBL6366190

SCHEMBL6366190

COc1ccc2c(c1)SCCCC2=O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.82
HTT P42858 1/20 0.82
ALDH1A1 P00352 3/20 0.52
RYR2 Q92736 5/20 0.48
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
METAP1 P53582 1/20 0.43
LMNA P02545 1/20 0.42
KCNH2 Q12809 1/20 0.40
MIF P14174 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDE3B Q13370 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67590 0.90 KDM4E (1.00) KDM4EHTTALDH1A1RYR2MAOA
SCHEMBL7222447 0.88 KDM4E (0.63) KDM4EHTTALDH1A1RYR2MAOA
SCHEMBL6284234 0.84 KDM4E (0.58) KDM4EHTTALDH1A1MAOAMAOB
SCHEMBL68574 0.80 KDM4E (0.71) KDM4EHTTALDH1A1RYR2MAOA
SCHEMBL20165113 0.79 KDM4E (0.53) KDM4EHTTALDH1A1CA2
SCHEMBL10335478 0.78 KDM4E (0.81) KDM4EHTTALDH1A1MAOACA1
SCHEMBL29596397 0.78 KDM4E (0.77) KDM4EHTTALDH1A1RYR2MAOA
SCHEMBL11283 0.78 KDM4E (0.77) KDM4EHTTALDH1A1RYR2MAOA
SCHEMBL24357640 0.77 KDM4E (0.51) KDM4EHTTALDH1A1MAOAMAOB
SCHEMBL29546224 0.77 KDM4E (0.51) KDM4EHTTALDH1A1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541809-B1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2025-06-25 EP disclosed
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2022-06-30 US disclosed
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2022-06-30 US disclosed
US-11149031-B2 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2021-10-19 US disclosed
US-11149031-B2 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2021-10-19 US disclosed
US-20200361918-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) 2020-11-19 US disclosed
US-20200361918-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) 2020-11-19 US disclosed
EP-3541809-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2019-09-25 EP disclosed
WO-2018091153-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2018-05-24 WO disclosed
WO-2018091153-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2018-05-24 WO disclosed
US-20170088546-A1 CARBOXAMIDE INHIBITORS NOVARTIS AG (CH) 2017-03-30 US disclosed
WO-2015173659-A2 CARBOXAMIDE DERIVATIVES NOVARTIS AG (CH) 2015-11-19 WO disclosed
US-8871756-B2 Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease HOFFMANN-LA ROCHE INC. (US) 2014-10-28 US disclosed
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN-LA ROCHE INC. 2013-08-01 US disclosed
US-20050282863-A1 Novel-N substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361918-A1 NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF ESR1, CYP19A1, ESR2 KDM4E 728/4885HTT 4661/4885ALDH1A1 1024/4885
US-11149031-B2 Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof ESR1, CYP19A1, ESR2 KDM4E 933/4885HTT 4524/4885ALDH1A1 835/4885
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE CFTR, H1-10, RECQL KDM4E 3397/4885HTT 2336/4885ALDH1A1 2189/4885
US-20170088546-A1 CARBOXAMIDE INHIBITORS SMURF1, SMURF2, SMYD2 KDM4E 122/4885HTT 4479/4885ALDH1A1 1440/4885
US-20050282863-A1 Novel-N substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators ESR1, ESR2, HSD17B11 KDM4E 862/4885HTT 245/4885ALDH1A1 443/4885
US-20220204488-A1 Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof ESR1, CYP19A1, GPER1 KDM4E 810/4885HTT 4530/4885ALDH1A1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.